Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus

Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus

Abstract We compared the effect of dapagliflozin versus glibenclamide on the ratio of lean-to total mass in patients with type 2 diabetes mellitus, carotid subclinical atherosclerosis, HbA1c 7.0–9.0% and 40–70 years-old. Ninety-eight patients (61% male; mean age 57 ± 7 years) were randomized into da...

Full description

Bibliographic Details
Main Authors: Vaneza Lira W. Wolf, Ikaro Breder, Luiz Sérgio F. de Carvalho, Alexandre A. S. Soares, Riobaldo M. Cintra, Joaquim Barreto, Daniel B. Munhoz, Sheila T. Kimura-Medorima, Wilson Nadruz, Gil Guerra-Júnior, Thiago Quinaglia, Elza Muscelli, Andrei C. Sposito, on behalf of Addenda-BHS2 trial investigators
Format: Article
Language:English
Published: Nature Publishing Group 2021-06-01
Series:Nutrition & Diabetes
Online Access:https://doi.org/10.1038/s41387-021-00160-5

Internet

https://doi.org/10.1038/s41387-021-00160-5

Similar Items